STT-002 / STCube Pharma - LARVOL DELTA

Targeting glycosylated PD-1 induces potent anti-tumor immunity. (PubMed, Cancer Res) - "The mAb STM418 specifically targeted glycosylated PD-1, exhibiting higher binding affinity to PD-1 than FDA-approved PD-1 antibodies, potently inhibiting PD-L1/PD-1 binding, and enhancing antitumor immunity. The monoclonal antibody STM418 specifically targeted glycosylated PD-1, exhibiting higher binding affinity to PD-1 than FDA-approved PD-1 antibodies, potently inhibiting PD-L1/PD-1 binding, and enhancing anti-tumor immunity. Together these findings provide novel insights into the functional significance of PD-1 glycosylation and offer a rationale for targeting glycosylated PD-1 as a potential strategy for immunotherapy."

Journal • Immune Modulation • Inflammation • Oncology

[SEN] ST Cube, acquired US patent for an improved new drug for immune checkpoint inhibitor' PD-1 antibody' [google translation] (Sedaily) - “ST Cube (052020)Announced on the 30th that it has acquired a US patent for the'PD-1 antibody' jointly developed with the MD Anderson Cancer Center…‘we discovered the antibody 'STM418' against PD-1 protein, an immune checkpoint material for cell membranes. It acquired a U.S. patent jointly with The University of Texas System of the MD Anderson Cancer Center.’”

Patent • Oncology

Samsung Biologics signs additional development and manufacturing agreement with STCube (PRNewswire) - "Samsung Biologics...has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate….Under the development and manufacturing agreement, Samsung Biologics will offer full scope of CDO services from cell line development, process development, non-clinical & clinical material manufacturing, to IND submission for global clinical trials of STM418."

Licensing / partnership • Oncology

[VIRTUAL] Targeting glycosylated PD-1 induces potent anti-tumor immunity (AACR-II 2020) - "A monoclonal antibody that specifically targets glycosylated PD-1, STM418, exhibits higher binding affinity to PD-1 than FDA-approved PD-1 antibodies, potently inhibits PD-L1/PD-1 binding, and enhances anti-tumor immunity. Our findings provide novel insights into the functional significance of PD-1 glycosylation and offer a rationale for targeting glycosylated PD-1 as a potential strategy for immunotherapy."

Oncology • CD8 • PD-1

[SEN] ST Cube announces results of PD-1 research on new drug candidates for immune checkpoint suppression at AACR (Sedaily) - "Bio-enterprise developing immuno-cancer drugs ST Cube (052020)Announced on the 23rd that it has announced the preclinical results for the new drug candidate, STM418, which is currently under development for PD-1 related immune checkpoint inhibitors at the annual American Association for Cancer Research (AACR) conference in 2020…In particular, in animal experiments, STM418 significantly inhibited tumor growth than the previously released PD-1 antibody drug, and the survival time was significantly extended when the tumor was injected into the transplanted animal."

Preclinical • Oncology